FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291004847> ?p ?o ?g. }

• W4291004847 endingPage "2382" @default.
• W4291004847 startingPage "2373" @default.
• W4291004847 abstract "Access to the liver transplant waitlist for patients with hepatocellular carcinoma (HCC) depends on tumour presentation, biology, and response to treatments. The Milan Criteria (MC) represent the benchmark for expanded criteria that incorporate additional prognostic factors. The purpose of this study was to determine the added value of skeletal muscle index (SMI) in HCC patients beyond the MC.Patients with HCC that were transplanted beyond the MC were included in this retrospective multicentre study. SMI was quantified using the Computed Tomography (CT) within 3 months prior to transplantation. Cox regression models were used to identify predictors of overall survival (OS). The discriminative performance of SMI extended Metroticket 2.0 and AFP models was also assessed.Out of 889 patients transplanted outside the MC, 528 had a CT scan within 3 months prior to liver transplantation (LT), of whom 176 (33%) were classified as sarcopenic. The median time between assessment of the SMI and LT was 1.8 months (IQR: 0.77-2.67). The median follow-up period was 5.1 95% CI [4.7-5.5] years, with a total of 177 recorded deaths from any cause. In a linear regression model with SMI as the dependent variable, only male gender (8.55 95% CI [6.51-10.59], P < 0.001) and body mass index (0.74 95% CI [0.59-0.89], P < 0.001) were significant. Univariable survival analysis of patients with sarcopenia versus patients without sarcopenia showed a significant difference in OS (HR 1.44 95% CI [1.07 - 1.94], P = 0.018). Also the SMI was significant (HR 0.98 95% CI [0.96-0.99], P = 0.014). The survival difference between the lowest SMI quartile versus the highest SMI quartile was significant (log-rank: P = 0.005) with 5 year OS of 57% and 71%, respectively. Data from 423 patients, describing 139 deaths, was used for multivariate analysis. Both sarcopenia (HR 1.45 95% CI [1.02 - 2.05], P = 0.036) and SMI were (HR 0.98 95% CI [0.95-0.99], P = 0.035) significant. On the survival scale this translates to a 5 year OS difference of 11% between sarcopenia and no sarcopenia. Whereas for SMI, this translates to a survival difference of 8% between first and third quartiles for both genders.Overall, we can conclude that higher muscle mass contributes to a better long-term survival. However, for individual patients, low muscle mass should not be considered an absolute contra-indication for LT as its discriminatory performance was limited." @default.
• W4291004847 created "2022-08-13" @default.
• W4291004847 creator A5000789082 @default.
• W4291004847 creator A5002115357 @default.
• W4291004847 creator A5004074611 @default.
• W4291004847 creator A5008262839 @default.
• W4291004847 creator A5009873146 @default.
• W4291004847 creator A5009926141 @default.
• W4291004847 creator A5010646464 @default.
• W4291004847 creator A5011416382 @default.
• W4291004847 creator A5011644837 @default.
• W4291004847 creator A5012385625 @default.
• W4291004847 creator A5013709976 @default.
• W4291004847 creator A5026028460 @default.
• W4291004847 creator A5027990022 @default.
• W4291004847 creator A5031240457 @default.
• W4291004847 creator A5033595772 @default.
• W4291004847 creator A5034151615 @default.
• W4291004847 creator A5035325944 @default.
• W4291004847 creator A5036202157 @default.
• W4291004847 creator A5039755661 @default.
• W4291004847 creator A5040481562 @default.
• W4291004847 creator A5047999645 @default.
• W4291004847 creator A5050149605 @default.
• W4291004847 creator A5051522350 @default.
• W4291004847 creator A5055559412 @default.
• W4291004847 creator A5058478839 @default.
• W4291004847 creator A5060612208 @default.
• W4291004847 creator A5062083639 @default.
• W4291004847 creator A5062157735 @default.
• W4291004847 creator A5064169322 @default.
• W4291004847 creator A5065733742 @default.
• W4291004847 creator A5067099584 @default.
• W4291004847 creator A5068166194 @default.
• W4291004847 creator A5069952259 @default.
• W4291004847 creator A5077710918 @default.
• W4291004847 creator A5083216661 @default.
• W4291004847 creator A5084860701 @default.
• W4291004847 creator A5086089467 @default.
• W4291004847 creator A5086326423 @default.
• W4291004847 creator A5086856138 @default.
• W4291004847 creator A5087012617 @default.
• W4291004847 creator A5087090863 @default.
• W4291004847 creator A5089044248 @default.
• W4291004847 creator A5091795929 @default.
• W4291004847 date "2022-08-10" @default.
• W4291004847 modified "2023-10-18" @default.
• W4291004847 title "Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria" @default.
• W4291004847 cites W1699364310 @default.
• W4291004847 cites W1964863204 @default.
• W4291004847 cites W1966230887 @default.
• W4291004847 cites W1974128990 @default.
• W4291004847 cites W1992692008 @default.
• W4291004847 cites W1996293915 @default.
• W4291004847 cites W2002998858 @default.
• W4291004847 cites W2008423320 @default.
• W4291004847 cites W2008655007 @default.
• W4291004847 cites W2008896731 @default.
• W4291004847 cites W2037246938 @default.
• W4291004847 cites W2056710503 @default.
• W4291004847 cites W2059426130 @default.
• W4291004847 cites W2059796825 @default.
• W4291004847 cites W2060123467 @default.
• W4291004847 cites W2063085086 @default.
• W4291004847 cites W2067724039 @default.
• W4291004847 cites W2069243984 @default.
• W4291004847 cites W2087000019 @default.
• W4291004847 cites W2090991937 @default.
• W4291004847 cites W2092646943 @default.
• W4291004847 cites W2097022747 @default.
• W4291004847 cites W2118865824 @default.
• W4291004847 cites W2119190881 @default.
• W4291004847 cites W2122939763 @default.
• W4291004847 cites W2143149622 @default.
• W4291004847 cites W2155243985 @default.
• W4291004847 cites W2160781843 @default.
• W4291004847 cites W2166406102 @default.
• W4291004847 cites W2277004004 @default.
• W4291004847 cites W2283978743 @default.
• W4291004847 cites W2315027248 @default.
• W4291004847 cites W2341485436 @default.
• W4291004847 cites W2419636070 @default.
• W4291004847 cites W2493246625 @default.
• W4291004847 cites W2556083310 @default.
• W4291004847 cites W2591717879 @default.
• W4291004847 cites W2597872842 @default.
• W4291004847 cites W2621134774 @default.
• W4291004847 cites W2736112965 @default.
• W4291004847 cites W2760934854 @default.
• W4291004847 cites W2772086822 @default.
• W4291004847 cites W2809335987 @default.
• W4291004847 cites W3043029167 @default.
• W4291004847 cites W3157370202 @default.
• W4291004847 cites W3191914634 @default.
• W4291004847 cites W4200379278 @default.
• W4291004847 doi "https://doi.org/10.1002/jcsm.13053" @default.
• W4291004847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36622940" @default.
• W4291004847 hasPublicationYear "2022" @default.

• next